Syndax Pharmaceuticals Inc SNDX
Syndax Pharmaceuticals Inc (Nasdaq: SNDX) is an oncology drug developer. Its lead program, Revuforj (revumenib), is in Phase 3 for R/R acute leukemia with KMT2A translocation; R/R AML with NPM1 mutation.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Revuforj (revumenib) | R/R acute leukemia with KMT2A translocation; R/R AML with NPM1 mutation | small molecule | Approved |
| Niktimvo (axatilimab-csfr) | chronic graft-versus-host disease | antibody | Approved |
| revumenib (NPM1m and KMT2Ar AML frontline combinations) | newly diagnosed NPM1m and KMT2Ar AML | small molecule | Phase 3 |
| axatilimab (newly diagnosed cGVHD) | newly diagnosed chronic GVHD | antibody | Phase 3 |
| revumenib (myelofibrosis proof-of-principle) | myelofibrosis | small molecule | Phase 1 |
| SNDX-62122 | myelofibrosis | small molecule | Pre-clinical |
| SNDX-4321 | EGFR-mutant NSCLC | small molecule | Pre-clinical |
Recent results and decisions
- Nov 2, 2026started RAVEN Phase 2 trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar AML patients fit for intensive chemotherapy is expected to initiate in 4Q26.
The Company expects the RAVEN trial to initiate in the fourth quarter of 2026.
Filing - Nov 2, 2026started The Company expects to initiate a Phase 1 trial of SNDX-4321 in EGFR-mutant NSCLC in 2027.
The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027.
Filing - Oct 31, 2026missed MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint, announced in October 2026.
In October 2026, the Company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.